Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03744962
NCT03744962UnknownNot Applicable

A Compare of Microsatellite Instability in Circulatory DNA and Tumor Tissue of Endometrial Cancer

Lei Li1 site in 1 country100 target enrollmentStarted: November 10, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
100
Locations
1
Primary Endpoint
Frequency of microsatellite instability
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer. These data will be used for the study of "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov).

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Confirmed primary endometrial cancer before any surgical or chemotherapy treatment
  • •Signed an approved informed consents
  • •Feasible for sampling

Exclusion Criteria

  • •Not meeting all of the inclusion criteria

Outcomes

Primary Outcomes

Frequency of microsatellite instability

Time Frame: Two years

Frequencies of different status of microsatellite instability (high microsatellite instability or microsatellite-stable) in the circulatory tumor DNA and in the tumor tissue

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Lei Li
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Lei Li

Professor

Peking Union Medical College Hospital

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid TumorsSolid Tumor
NCT03596593Peking University8,000
Recruiting
Not Applicable
ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaEsophageal Squamous Cell Carcinoma
NCT05426850Fudan University100
Completed
Not Applicable
Molecular Characteristics of Early-onset Compared With Late-onset Colorectal CancerMicrosatellite InstabilityColorectal Cancer
NCT06238193The First Affiliated Hospital with Nanjing Medical University11,344
Active, not recruiting
Unknown
Whether high-risk features (HRFs) on the recurrence or microsatellite instability (MSI) status are predictive markers for adjuvant chemotherapy (ACT) in patients with stage II colon cancer is uncertain. This study aimed to examine the impact of HRFs and MSI on the prediction of the benefits of ACT in patients with stage II colon cancer. This multi-center retrospective study included 1801 patients with resected stage II colon cancer diagnosed at 17 university-affiliated hospitals between January 2010 and December 2017.Neoplasms
KCT0009579Keimyung University Dongsan Hospital1,300
Unknown
Not Applicable
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation SequencingColorectal Neoplasms
NCT03561350Shanghai Minimally Invasive Surgery Center60